東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Antibody-drug conjugates = fundament...

Olivier, Kenneth J., (Jr.,) (1968-)

Linked to FindBook

Google Book

Amazon

博客來

Antibody-drug conjugates = fundamentals, drug development, and clinical outcomes to target cancer /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Antibody-drug conjugates/ edited by Kenneth J. Olivier Jr., Sara A. Hurvitz
Reminder of title:	fundamentals, drug development, and clinical outcomes to target cancer /
other author:	Olivier, Kenneth J.,
Published:	Hoboken, New Jersey :John Wiley & Sons, Inc., : [2017],
Description:	1 online resource
[NT 15003449]:	Typical antibody-drug conjugates / John Lambert -- Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper -- Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross -- Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha -- Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake -- QC assay development / Xiao-Hong Chen and Mate Tolnay -- Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris -- Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel -- Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta -- Pharmacokinetics of antibody-drug conjugates / Amrita Kamath -- Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson -- Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta -- Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin -- ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino -- ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead -- Radioimmunotherapy / Jeffrey Wong and Savita Dandapani -- Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy -- Antibody-drug conjugates : the next evolution in the cure for cancer -- William C. Olson and Amy Q. Han
Subject:	Antibodies, Monoclonal -
Online resource:	http://onlinelibrary.wiley.com/book/10.1002/9781119060727Connect to resource
ISBN:	9781119060727

Antibody-drug conjugates = fundamentals, drug development, and clinical outcomes to target cancer /
Antibody-drug conjugates (Olivier)

Antibody-drug conjugatesfundamentals, drug development, and clinical outcomes to target cancer /[electronic resource] :edited by Kenneth J. Olivier Jr., Sara A. Hurvitz - Hoboken, New Jersey :John Wiley & Sons, Inc.,[2017] - 1 online resource

Includes bibliographical references and index

Typical antibody-drug conjugates / John Lambert -- Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper -- Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross -- Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha -- Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake -- QC assay development / Xiao-Hong Chen and Mate Tolnay -- Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris -- Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel -- Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta -- Pharmacokinetics of antibody-drug conjugates / Amrita Kamath -- Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson -- Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta -- Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin -- ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino -- ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead -- Radioimmunotherapy / Jeffrey Wong and Savita Dandapani -- Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy -- Antibody-drug conjugates : the next evolution in the cure for cancer -- William C. Olson and Amy Q. Han

Available to OhioLINK libraries

ISBN: 9781119060727

LCCN: 2016034128Subjects--Topical Terms:

3199369
Antibodies, Monoclonal
Index Terms--Genre/Form:

959526
Electronic books

LC Class. No.: RS431.A64

Dewey Class. No.: 615.7/98

National Library of Medicine Call No.: QW 575.5.A6

Antibody-drug conjugates = fundamentals, drug development, and clinical outcomes to target cancer /
LDR:03219cmm 22003738i 4500 001 2080159
003 OCoLC
005 20161130101607.4
006 m o d
007 cr |||||||||||
008 170606s2017 nju ob 001 0 eng
010 $a 2016034128
019 $a 964291642
020 $a 9781119060727
020 $a 1119060729
020 $a 9781119060802
020 $a 9781119060680
020 $a 111906080X
035 $a (OCoLC)954037554
035 $a 954037554
040 $a DLC $b eng $e rda $c DLC $d OCLCO $d DG1 $d N$T $d OCLCO $d YDX
042 $a pcc
050 1 0 $a RS431.A64
060 1 0 $a QW 575.5.A6
072 7 $a MED $x 071000 $2 bisacsh
082 0 0 $a 615.7/98 $2 23
130 0 $a Antibody-drug conjugates (Olivier) $3 3199364
245 1 0 $a Antibody-drug conjugates $h [electronic resource] : $b fundamentals, drug development, and clinical outcomes to target cancer / $c edited by Kenneth J. Olivier Jr., Sara A. Hurvitz
260 $a Hoboken, New Jersey : $b John Wiley & Sons, Inc., $c [2017]
263 $a 1611
300 $a 1 online resource
504 $a Includes bibliographical references and index
505 0 # $a Typical antibody-drug conjugates / John Lambert -- Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper -- Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross -- Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha -- Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake -- QC assay development / Xiao-Hong Chen and Mate Tolnay -- Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris -- Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel -- Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta -- Pharmacokinetics of antibody-drug conjugates / Amrita Kamath -- Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson -- Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta -- Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin -- ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino -- ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead -- Radioimmunotherapy / Jeffrey Wong and Savita Dandapani -- Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy -- Antibody-drug conjugates : the next evolution in the cure for cancer -- William C. Olson and Amy Q. Han
506 # $a Available to OhioLINK libraries
650 # 2 $a Antibodies, Monoclonal $3 3199369
650 # 2 $a Antineoplastic Agents $3 931435
650 # 0 $a Antibody-toxin conjugates $3 3199367
650 # 2 $a Immunoconjugates $3 3199368
650 # 2 $a Neoplasms $x drug therapy $3 929235
655 # 4 $a Electronic books $3 959526
700 1 # $a Olivier, Kenneth J., $c Jr., $d 1968- $e editor $3 3199365
700 1 # $a Hurvitz, Sara A., $d 1970- $e editor $3 3199366
710 2 # $a Ohio Library and Information Network $3 2178037
776 0 8 $i Print version: $d Hoboken, New Jersey : John Wiley & Sons, Inc., [2017] $z 9781119060680 $w (DLC) 2016032954
856 4 0 $3 Wiley Online Library $u http://onlinelibrary.wiley.com/book/10.1002/9781119060727 $z Connect to resource